Mereo BioPharma’s CEO discusses recent setrusumab data in Osteogenesis Imperfecta and the future of alvelestat
Denise Scots-Knight describes what Mereo and its partner Ultragenyx have seen in setrusumab data over time, and her description of the clinical benefit to patients’ lives. Plus, the role that the company’s alvelestat program could play in lung conditions.